Musculoskeletal immune-related adverse events in 927 patients treated with immune checkpoint inhibitors for solid cancer
Authors' conclusion
Musculoskeletal irAEs in this large cohort of patients treated with ICI were frequent (12.7%), mostly mild and well tolerated.
Study context
- Population
- Patients who received immune checkpoint inhibitors (ICI) for solid tumor, 07/27/2014 to 05/08/2020, medical oncology department of the Institut Paoli-Calmettes, Marseille, France
- Participants
- 927 patients
- Outcome
- Musculoskeletal immune-related adverse events (irAEs) (prevalence and characteristics)
Methodological detailssingle-centre
- Single-centre
Main finding
As reported in the abstract
Musculoskeletal irAE
Patients with a musculoskeletal irAE
118
12.7%
Arthralgias and myalgias (most frequent)
9.8%
Inflammatory rheumatic features (elevated acute phase reactants, negative immunological markers)
36
3.9%
Median time of onset, months
2
95% CI 1.8; 2.7
Observational data: associations, not effects.
Further findings
Tumor response at 3 months
- Did not differ according to musculoskeletal irAE severity, type of manifestation (arthralgias/myalgias vs inflammatory rheumatic features), pain patterns (mechanical vs inflammatory) or irAE treatments
Original publication
Musculoskeletal immune-related adverse events in 927 patients treated with immune checkpoint inhibitors for solid cancer. Joint Bone Spine. Published 15 September 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →